AstraZeneca faces more doubts

British drug maker, AstraZeneca, may have provided an incomplete view of the efficacy data, from a large scale trial it conducted in the US.

Federal health officials in America, have expressed concern that the drug company used outdated information.

The report being called into question, was released on Monday and could impact the emergency authorisation the company is seeking in the US. 

Wits Professor of Vaccinology, Dr Shabir Madhi, the lead investigator in the South African trial, joined us to discuss this in depth.

He says it is unfortunate that some countries, including South Africa, decided not to use of the vaccine, as it could prove useful going forward.